I was impressed with the tone of the 10K. It was a report of last years mess but the new team is upbeat and lays out a good plan
He does a good job of telling it like it is imho. thanks for posting.
I put in an order for 12K at 2.00 this morning and the price jumped immediately so I moved my order up to 2.01 and the price jumped to 2.04. That went on all day and I got filled for less than 2K. I should have just paid market at the open because I knew this would bounce.
Platinum is taking over this company one way or another imho. They will either get the management change we all need or they will buy the rest of the shares and take it over. All they want is to get the stock back to $20 or $30 where it should be and the Symphony system approved by FDA and in China.
You don't have a choice when getting a tetanus shot. But if people have a choice of using a needle or a sensor with no needle and get the same accuracy to measure blood glucose then 100% will choose to use no needle.
Anyone who thinks otherwise is ignoring the facts.
The need to continually self-monitor glucose levels is an all too familiar task for people living with diabetes. Unfortunately, frequent needle pricks, drawing blood and covering expenses all come with the territory.
For diabetics on higher insulin doses, this could mean getting stuck with needles many times a day.
Echo Therapeutics is poised to change this protocol by taking the needle out of the equation. Echo recently announced plans to begin marketing its product to diabetics in Europe and will complete its final U.S. to test in 2014 on its flagship product – a needle-free glucose monitoring device called the Symphony CGM System.
Unlike other devices on the market, this wireless transdermal system doesn’t require the glucose sensor to be inserted into the skin. This means no needles, no blood, and no pain. Skin permeation technology is Echo’s area of specialty). Pending FDA approval, the company plans to commercialize the Symphony CGM System for use in hospital critical care units in the U.S. and expand into diabetes patients and pediatrics later in the year.
“For me, I would jump at the opportunity to no longer use needles,” said Louise Kuchynskas, 58, who’s been battling diabetes since childhood. Her diagnosis requires four daily insulin injections, in addition to six glucose tests a day.
“I have to take the machines with me wherever I go,” said Kuchynskas. “It’s not easy, and it leaves my fingers tender. Sometimes I feel like all I do is poke myself with needles.”
According to the National Diabetes Education Program, 25.8 million Americans have diabetes.
Thanks. I'm glad to see someone stand up to the clowns that ran this company into the ground but I doubt it will change anything. The CEO owns 3000 shares of the stock. He doesnt have any faith in the company and doesnt give a hoot if it goes out of business.
The platinum montaur offer did more to help the stock than anything else. IMHO the market likes it. Management should take notice.
technically they reported first two months of sales but that number had no actual sales because sales take eight weeks to get hospitals to approve the switch over and lymphoseek was on the market for eight weeks
Sentiment: Strong Buy
Hitting $13 in PM. I hope nobody shorted yesterday. Here's the thing. IPI is a US only marketer and they have the lower production costs and more importantly lower bulk transportation costs to the end customers which gives them a competitive advantage. The earnings report shows them spending smartly to capitalize on those strengths. I would buy IPI over POT at this point.
a partnership announcement with upfront cash will push this to $10 or $15 (the old $1 to $1.50)
PC's are in decline but don't count on the cloud becoming the only game in town. 83% of people polled are still uncomfortable with the idea of uploading all their personal information to a data center in India or Pakistan. If it's on your hard drive you still have control.
50% does not excite me. A third grader would probably score at that level. They have a long way to go before this becomes a realistic commercial endeavor. There are more promising platforms in development.
I am involved in a trust that is invested in the Platinum funds. We receive periodic reports of all positions and trades for each quarter, long, short, long-short and derivatives. One of their subsidiaries held one million options in NAVB early this year. That's the only NEOP-NAVB transactions outside their beneficial interest in the preferred stock, warrants and reported long position (NAVB is one of their largest holdings). Platinum has never reported a short of NEOP-NAVB and I know that for fact. I'm not sure where your information comes from but it did not come from Platinum.